Characterization of immunostimulating complexes (ISCOMS) of HIV-1.

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Characterization of immunostimulating complexes (ISCOMS) of HIV-1.

Viral Immunol. 1990 Fall;3(3):195-206. Unique Identifier : AIDSLINE MED/91076980
Hoglund S; Akerblom L; Ozel M; Villacres M; Eriksson M; Gelderblom HR; Arthur L; Morein B; Institute of Biochemistry, Biomedical Center, Uppsala, Sweden.

Abstract: HIV-1, strain HTLV-III, propagated in H9 cells and purified by sucrose gradient centrifugation, was used as native antigen source for the preparation of immunostimulating complexes, HIV-iscoms. The major antigen detected in the iscom was the cell-derived HLA-DR, which readily could be removed from the virus lysate by immunosorbent. In the iscoms the HIV structural proteins MA p17, p55 and TM gp41 were identified; SU gp120 was present in only minute amounts in the virus lysate. The iscom particles appeared well preserved after freeze drying with a round shape, approximately 35 nm in diameter, comprising morphological subunits, assembled with icosahedral symmetry. Immunization experiments in mice reflected the antigen content of the iscoms. High antibody response was induced to HLA-DR in non-depleted iscoms. Major humoral responses were observed to the viral structural proteins MA p17, CA p24, p55, and also to TM gp41. A low or negligible antibody response to SU gp120 was induced by the HIV-iscoms. The negligible response was, however, overcome by the addition of recombinant gp160 to the virus lysate prior to formation of iscoms, resulting in a preparation evoking a clear serum antibody to gp160.

Keywords: Animal Antibodies, Monoclonal Blotting, Western Comparative Study Electrophoresis, Polyacrylamide Gel Gene Products, env/ADMINISTRATION & DOSAGE/IMMUNOLOGY Gene Products, gag/ADMINISTRATION & DOSAGE/IMMUNOLOGY Human HIV Antibodies/BIOSYNTHESIS/IMMUNOLOGY HIV Antigens/ADMINISTRATION & DOSAGE/*IMMUNOLOGY HIV Envelope Protein gp120/ADMINISTRATION & DOSAGE/IMMUNOLOGY HIV Envelope Protein gp41/ADMINISTRATION & DOSAGE/IMMUNOLOGY HIV Seropositivity/IMMUNOLOGY HIV-1/*IMMUNOLOGY HLA-DR Antigens/IMMUNOLOGY Mice Protein Precursors/ADMINISTRATION & DOSAGE/IMMUNOLOGY Recombinant Proteins Saponins Viral Vaccines/*IMMUNOLOGY JOURNAL ARTICLE
910430
M9140664

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .